Search This Blog

Friday, May 24, 2019

BioCryst downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital analyst Brian Abrahams downgraded BioCryst Pharmaceuticals to Sector Perform from Outperform and lowered his price target for the shares to $4.50 from $16.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)